<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-05-21T08:56:48.723Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JCEM Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">JCEM Case Rep</journal-id><journal-id journal-id-type="publisher-id">jcemcr</journal-id><journal-title-group><journal-title>JCEM Case Reports</journal-title></journal-title-group><issn pub-type="epub">2755-1520</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40401174</article-id><article-id pub-id-type="pmc">PMC12093095</article-id><article-id pub-id-type="doi">10.1210/jcemcr/luaf109</article-id><article-id pub-id-type="publisher-id">luaf109</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject><subject>AcademicSubjects/MED00160</subject><subject>AcademicSubjects/MED00250</subject><subject>AcademicSubjects/MED00300</subject><subject>AcademicSubjects/MED00905</subject></subj-group></article-categories><title-group><article-title>The Challenge of Type 3c Diabetes: From Accurate Diagnosis to Effective Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-0120-4731</contrib-id><name><surname>Milani</surname><given-names>Ilaria</given-names></name><aff>
<institution>Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome</institution>, <addr-line>Latin 04100</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Guarisco</surname><given-names>Gloria</given-names></name><aff>
<institution>Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome</institution>, <addr-line>Latin 04100</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Chinucci</surname><given-names>Marianna</given-names></name><aff>
<institution>Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome</institution>, <addr-line>Latin 04100</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Gaita</surname><given-names>Chiara</given-names></name><aff>
<institution>Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome</institution>, <addr-line>Latin 04100</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5606-8448</contrib-id><name><surname>Leonetti</surname><given-names>Frida</given-names></name><aff>
<institution>Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome</institution>, <addr-line>Latin 04100</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1674-6686</contrib-id><name><surname>Capoccia</surname><given-names>Danila</given-names></name><aff>
<institution>Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome</institution>, <addr-line>Latin 04100</addr-line>, <country country="IT">Italy</country></aff><xref rid="luaf109-cor1" ref-type="corresp"/><!--danila.capoccia@uniroma1.it--></contrib></contrib-group><author-notes><corresp id="luaf109-cor1">
<bold>Correspondence</bold>: Danila Capoccia, MD, PhD, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latin 04100, Italy. Email: <email>danila.capoccia@uniroma1.it</email>.</corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-05-21"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><volume>3</volume><issue>7</issue><elocation-id>luaf109</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2025</year></date><date date-type="editorial-decision"><day>29</day><month>4</month><year>2025</year></date><date date-type="corrected-typeset"><day>21</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.</license-p></license></permissions><self-uri xlink:href="luaf109.pdf"/><abstract><title>Abstract</title><p>Type 3c diabetes mellitus is a secondary form of diabetes associated with pancreatic disease, primarily chronic pancreatitis, which impairs insulin and glucagon secretion, resulting in inadequate glycemic control. Often misdiagnosed as other types of diabetes, such as type 1 or type 2 diabetes mellitus, type 3c diabetes mellitus is characterized by significant glucose variability, increased insulin requirements, and risk of hypoglycemia.</p><p>This case report describes a 24-year-old man with a history of hereditary chronic pancreatitis resulting from a serine protease 1 (<italic toggle="yes">PRSS1</italic>) gene pathogenic variant, who presented with fasting hyperglycemia and elevated glycated hemoglobin requiring early insulin therapy. In the absence of symptoms of exocrine pancreatic insufficiency, specific diagnostic criteria confirmed the diagnosis of pancreatogenic diabetes, and the use of a glucose monitoring system proved essential for optimal management. Therefore, appropriate screening for diabetes in patients with hereditary chronic pancreatitis, combined with accurate diagnosis and close monitoring, can lead to the development of individualized strategies to prevent complications and improve glycemic control.</p></abstract><kwd-group><kwd>type 3c diabetes mellitus</kwd><kwd>chronic pancreatitis</kwd><kwd>glucose monitoring</kwd><kwd>diagnosis</kwd><kwd>treatment</kwd></kwd-group><counts><page-count count="6"/></counts></article-meta></front><body><sec sec-type="intro" id="luaf109-s1"><title>Introduction</title><p>Type 3c diabetes mellitus (T3cDM) is a distinct form of diabetes recognized by both the American Diabetes Association and the World Health Organization [<xref rid="luaf109-B1" ref-type="bibr">1</xref>]. Known as &#x0201c;pancreatogenic or pancreoprivic,&#x0201d; it is a secondary form of diabetes associated with diseases of the exocrine pancreas [<xref rid="luaf109-B2" ref-type="bibr">2</xref>], with chronic pancreatitis (CP) being the primary cause (79%), followed by pancreatic ductal adenocarcinoma (8%), hemochromatosis (7%), cystic fibrosis (4%), and pancreatic surgery (2%) [<xref rid="luaf109-B3" ref-type="bibr">3</xref>]. Genetic pathogenic variants are strongly associated with the development of pancreatic diseases. The c.311T &#x0003e; C (p.L104P) pathogenic variant of the serine protease 1 (<italic toggle="yes">PRSS1</italic>) gene (encoding cationic trypsinogen) is frequently found in families with hereditary chronic pancreatitis (HCP) [<xref rid="luaf109-B4" ref-type="bibr">4</xref>, <xref rid="luaf109-B5" ref-type="bibr">5</xref>], often presents as recurrent acute pancreatitis and serves as precursor to CP [<xref rid="luaf109-B1" ref-type="bibr">1</xref>, <xref rid="luaf109-B6" ref-type="bibr">6</xref>, <xref rid="luaf109-B7" ref-type="bibr">7</xref>]. Genetic testing is used to diagnose this familial disorder that predisposes to complications such as T3cDM. Approximately 48% of individuals with <italic toggle="yes">PRSS1</italic>-associated HCP will develop diabetes, a prevalence similar to other forms of CP [<xref rid="luaf109-B8" ref-type="bibr">8</xref>].</p><p>T3cDM is difficult to diagnose, leading to underdiagnosis [<xref rid="luaf109-B1" ref-type="bibr">1</xref>]. It affects approximately 5% to 10% of people with diabetes but is often misclassified as type 1 (T1DM) or type 2 (T2DM) diabetes mellitus [<xref rid="luaf109-B9" ref-type="bibr">9</xref>] its unique clinical and metabolic features [<xref rid="luaf109-B10" ref-type="bibr">10</xref>]. To improve diagnosis, Ewald and Bretzel proposed specific diagnostic criteria [<xref rid="luaf109-B11" ref-type="bibr">11</xref>, <xref rid="luaf109-B12" ref-type="bibr">12</xref>], including testing for exocrine pancreatic insufficiency (fecal monoclonal elastase-1 test or direct functional testing), pancreatic imaging (endoscopic ultrasound, magnetic resonance imaging, and computed tomography), and the absence of autoimmune markers typical of T1DM [<xref rid="luaf109-B13" ref-type="bibr">13</xref>]. Assessment of &#x003b2;-cell function (eg, C-peptide levels) or low levels of lipid-soluble vitamins (A, D, E, K) are additional criteria [<xref rid="luaf109-B14" ref-type="bibr">14</xref>].</p><p>These criteria are not yet standardized and can be difficult to apply, especially in cases that overlap with T1DM or long-standing T2DM complicated by exocrine pancreatic insufficiency [<xref rid="luaf109-B2" ref-type="bibr">2</xref>]; however, their early adoption can improve the detection and management of T3cDM [<xref rid="luaf109-B9" ref-type="bibr">9</xref>, <xref rid="luaf109-B13" ref-type="bibr">13</xref>]. The unique pathophysiology of T3cDM, which includes pancreatic inflammation, fibrosis, and loss of insulin-, glucagon-, and pancreatic polypeptide-secreting cells, requires tailored treatment strategies [<xref rid="luaf109-B2" ref-type="bibr">2</xref>, <xref rid="luaf109-B15" ref-type="bibr">15</xref>].</p><p>The refinement and use of these diagnostic criteria is essential for patients who may not have typical signs of exocrine pancreatic insufficiency but who could benefit from early insulin therapy and close monitoring.</p></sec><sec id="luaf109-s2"><title>Case Presentation</title><p>At the first visit, a 24-year-old man was referred for evaluation of fasting hyperglycemia and elevated glycated hemoglobin (HbA1c) (<xref rid="luaf109-T1" ref-type="table">Table 1</xref>). He was overweight (body mass index = 27.8&#x02005;kg/m<sup>2</sup>), had normal blood pressure (130/80&#x02005;mm Hg), and reported no acute symptoms of hyperglycemia. The patient had a family history of CP, with his mother developing diabetes, probably secondary to pancreatitis. From 2014 to 2019, he had multiple documented episodes of acute pancreatitis with elevated amylase and lipase levels. Genetic testing revealed a heterozygous pathogenic variant in the <italic toggle="yes">PRSS1</italic> gene (c.311T &#x0003e; C, p.L104P), which was also found in several family members. Additional testing for other pancreatitis risk genes (<italic toggle="yes">SPINK1, PRSS2, CTRC, CASR, CTSB, KRT8</italic>, and <italic toggle="yes">CPA1</italic>) were negative. A magnetic resonance imaging scan and computed tomography scan in 2020 showed pancreatic atrophy, especially in the body, and chronic inflammation with a tortuous common bile duct. Since 2020, he has had no further episodes of acute pancreatitis. Pancreatic enzyme replacement therapy and proton pump inhibitors were recommended during his hospitalizations.</p><table-wrap position="float" id="luaf109-T1"><label>Table 1.</label><caption><p>Anthropometric and biochemical test at first visit and during follow-up</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Anthropometric and biochemical test</th><th align="left" rowspan="1" colspan="1">First visit</th><th align="left" rowspan="1" colspan="1">3 months</th><th align="left" rowspan="1" colspan="1">6 months</th><th align="left" rowspan="1" colspan="1">9 months</th><th align="left" rowspan="1" colspan="1">12 months</th><th align="left" rowspan="1" colspan="1">Normal reference range</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">BMI</td><td rowspan="1" colspan="1">27.8 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">29 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">28.7 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">28.7 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">28.8 kg/m<sup>2</sup></td><td rowspan="1" colspan="1">18.5-24.9 kg/m<sup>2</sup></td></tr><tr><td rowspan="1" colspan="1">Glycemia</td><td rowspan="1" colspan="1">189&#x02005;mg/dL (10.5&#x02005;mmol/L)</td><td rowspan="1" colspan="1">170 mg/dL (9.44&#x02005;mmol/L)</td><td rowspan="1" colspan="1">110 mg/dL (6.11&#x02005;mmol/L)</td><td rowspan="1" colspan="1">119 mg/dL (6.61&#x02005;mmol/L)</td><td rowspan="1" colspan="1">112 mg/dL (6.22&#x02005;mmol/L)</td><td rowspan="1" colspan="1">70-105&#x02005;mg/dL (3.89-5.83&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1">Glycated hemoglobin</td><td rowspan="1" colspan="1">9.3% (78&#x02005;mmol/mol)</td><td rowspan="1" colspan="1">8.9% (74&#x02005;mmol/mol)</td><td rowspan="1" colspan="1">7.6% (60&#x02005;mmol/mol)</td><td rowspan="1" colspan="1">8.1% (65 mmol/mol)</td><td rowspan="1" colspan="1">6.9% (52&#x02005;mmol/mol)</td><td rowspan="1" colspan="1">4.3-5.9% (20-42&#x02005;mmol/mol)</td></tr><tr><td rowspan="1" colspan="1">C-peptide</td><td rowspan="1" colspan="1">0.8&#x02005;ng/mL (0.26 nmol/L)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">0.8-3.1&#x02005;ng/mL (0.26-1.03&#x02005;nmol/L)</td></tr><tr><td rowspan="1" colspan="1">Total cholesterol</td><td rowspan="1" colspan="1">208&#x02005;mg/dL (5.37&#x02005;mmol/L)</td><td rowspan="1" colspan="1">218 mg/dL (5.63&#x02005;mmol/L)</td><td rowspan="1" colspan="1">168 mg/dL (20-42&#x02005;mmol/L)</td><td rowspan="1" colspan="1">206 mg/dL (4.34&#x02005;mmol/L)</td><td rowspan="1" colspan="1">156 mg/dL (4.03&#x02005;mmol/L)</td><td rowspan="1" colspan="1">&#x0003c;200 mg/dL (5.17&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1">LDL cholesterol</td><td rowspan="1" colspan="1">146&#x02005;mg/dL (3.77&#x02005;mmol/L)</td><td rowspan="1" colspan="1">156 mg/dL (4.03&#x02005;mmol/L)</td><td rowspan="1" colspan="1">109 mg/dL (2.82&#x02005;mmol/L)</td><td rowspan="1" colspan="1">148.4&#x02005;mg/dL (3.83&#x02005;mmol/L)</td><td rowspan="1" colspan="1">102.2&#x02005;mg/dL (2.64&#x02005;mmol/L)</td><td rowspan="1" colspan="1">&#x0003c;100&#x02005;mg/dL (2.6&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1">HDL cholesterol</td><td rowspan="1" colspan="1">42&#x02005;mg/dL (1.08&#x02005;mmol/L)</td><td rowspan="1" colspan="1">42 mg/dL (1.08&#x02005;mmol/L)</td><td rowspan="1" colspan="1">44 mg/dL (1.13&#x02005;mmol/L)</td><td rowspan="1" colspan="1">46 mg/dL (1.18&#x02005;mmol/L)</td><td rowspan="1" colspan="1">43 mg/dL (1.11&#x02005;mmol/L)</td><td rowspan="1" colspan="1">&#x0003e;45 mg/dL (1.16 mmol/L)</td></tr><tr><td rowspan="1" colspan="1">Triglycerides</td><td rowspan="1" colspan="1">98&#x02005;mg/dL (1.10&#x02005;mmol/L)</td><td rowspan="1" colspan="1">100 mg/dL (1.12&#x02005;mmol/L)</td><td rowspan="1" colspan="1">72 mg/dL (0.81&#x02005;mmol/L)</td><td rowspan="1" colspan="1">58 mg/dL (0.65&#x02005;mmol/L)</td><td rowspan="1" colspan="1">54 mg/dL (0.61&#x02005;mmol/L)</td><td rowspan="1" colspan="1">&#x0003c;150&#x02005;mg/dL (1.69&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1">Creatinine</td><td rowspan="1" colspan="1">0.83&#x02005;mg/dL (0.07&#x02005;mmol/L)</td><td rowspan="1" colspan="1">0.89&#x02005;mg/dL (0.08&#x02005;mmol/L)</td><td rowspan="1" colspan="1">1.02&#x02005;mg/dL (0.09&#x02005;mmol/L)</td><td rowspan="1" colspan="1">1.17&#x02005;mg/dL (0.10&#x02005;mmol/L)</td><td rowspan="1" colspan="1">1.08&#x02005;mg/dL (0.09&#x02005;mmol/L)</td><td rowspan="1" colspan="1">0.73-1.18&#x02005;mg/dL (0.06-0.104&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1">eGFR MDRD</td><td rowspan="1" colspan="1">118&#x02005;mL/min</td><td rowspan="1" colspan="1">108&#x02005;mL/min</td><td rowspan="1" colspan="1">93 mL/min</td><td rowspan="1" colspan="1">74 mL/min</td><td rowspan="1" colspan="1">85.92&#x02005;mL/min</td><td rowspan="1" colspan="1">&#x0003e;60&#x02005;mL/min</td></tr><tr><td rowspan="1" colspan="1">GOT</td><td rowspan="1" colspan="1">64&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">18&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">5-34&#x02005;U/L</td></tr><tr><td rowspan="1" colspan="1">GPT</td><td rowspan="1" colspan="1">38&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">37&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">0-55&#x02005;U/L</td></tr><tr><td rowspan="1" colspan="1">Amylase</td><td rowspan="1" colspan="1">36&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">6&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">28-100&#x02005;U/L</td></tr><tr><td rowspan="1" colspan="1">Lipase</td><td rowspan="1" colspan="1">11&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">7&#x02005;U/L</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x0003c;59&#x02005;U/L</td></tr><tr><td rowspan="1" colspan="1">Fecal elastase</td><td rowspan="1" colspan="1">200&#x02005;mcg/g</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x0003e;200&#x02005;mcg/g</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; GOT = glutamic oxaloacetic transaminase; GPT = glutamic pyruvic transaminase; MDRD, Modification of Diet in Renal Disease.</p></fn></table-wrap-foot></table-wrap></sec><sec id="luaf109-s3"><title>Diagnostic Assessment</title><p>At the first visit, given the uncontrolled glycemic control of the patient, the medical history of HCP and the young age, further testing was required according to the Ewald and Bretzel criteria to differentiate the diagnosis. These tests included T1DM autoantibodies, fecal elastase 1 levels, pancreatic imaging, and plasma C-peptide levels to assess &#x003b2;-cell function. Because of his high HbA1c, insulin glargine U 300 (10&#x02005;IU) and metformin (500&#x02005;mg twice daily) were prescribed.</p><p>Over the next year, the patient did not report any gastrointestinal symptoms of exocrine pancreatic insufficiency and therefore did not adhere to the recommended pancreatic enzyme replacement therapy and proton pump inhibitor therapy or attend a specialized outpatient clinic.</p><p>At a 3-month follow-up, laboratory test confirmed a second high glucose and HbA1c value (<xref rid="luaf109-T2" ref-type="table">Table 2</xref>) according to the American Diabetes Association criteria for diabetes [<xref rid="luaf109-B12" ref-type="bibr">12</xref>]. Autoimmune markers for T1DM (anti-GAD, anti-ICA, and anti-Znt8) were negative, but C-peptide fasting levels indicated reduced &#x003b2;-cell function (<xref rid="luaf109-T1" ref-type="table">Table 1</xref>). Pancreatic imaging (endoscopic ultrasound) showed heterogeneous and atrophic pancreatic parenchyma, hyperechoic clots in the lumen, and dilated main (9&#x02005;mm) and accessory pancreatic ducts without evidence of cancer. A diagnosis of HCP-related T3cDM was made.</p><table-wrap position="float" id="luaf109-T2"><label>Table 2.</label><caption><p>Self-blood glucose monitoring</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">Before breakfast</th><th align="left" rowspan="1" colspan="1">2&#x02005;hours after breakfast</th><th align="left" rowspan="1" colspan="1">Before lunch</th><th align="left" rowspan="1" colspan="1">2&#x02005;hours after lunch</th><th align="left" rowspan="1" colspan="1">Before dinner</th><th align="left" rowspan="1" colspan="1">2&#x02005;hours after dinner</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">124&#x02005;mg/dL (6.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1">117&#x02005;mg/dL (6.5&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">125&#x02005;mg/dL (6.9&#x02005;mmol/L)</td><td rowspan="1" colspan="1">96&#x02005;mg/dL (5.3&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">139&#x02005;mg/dL (7.7&#x02005;mmol/L)</td><td rowspan="1" colspan="1">127&#x02005;mg/dL (7.0 mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">121&#x02005;mg/dL (6.7&#x02005;mmol/L)</td><td rowspan="1" colspan="1">101&#x02005;mg/dL (5.6&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">117&#x02005;mg/dL (6.5&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">90&#x02005;mg/dL (5&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">91&#x02005;mg/dL (5.05&#x02005;mmol/L)</td><td rowspan="1" colspan="1">108&#x02005;mg/dL (6&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">132&#x02005;mg/dL (7.3&#x02005;mmol/L)</td><td rowspan="1" colspan="1">114&#x02005;mg/dL (6.3&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">130&#x02005;mg/dL (7.2&#x02005;mmol/L)</td><td rowspan="1" colspan="1">98&#x02005;mg/dL (5.4&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">100&#x02005;mg/dL (5.5&#x02005;mmol/L)</td><td rowspan="1" colspan="1">115&#x02005;mg/dL (6.4&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">87&#x02005;mg/dL (4.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">90&#x02005;mg/dL (5&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">107&#x02005;mg/dL (5.9&#x02005;mmol/L)</td><td rowspan="1" colspan="1">79&#x02005;mg/dL (4.4&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">121&#x02005;mg/dL (6.7&#x02005;mmol/L)</td><td rowspan="1" colspan="1">103&#x02005;mg/dL (5.7&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">89&#x02005;mg/dL (4.9&#x02005;mmol/L)</td><td rowspan="1" colspan="1">88&#x02005;mg/dL (4.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">102&#x02005;mg/dL (5.6&#x02005;mmol/L)</td><td rowspan="1" colspan="1">119&#x02005;mg/dL (6.6 mmol/L)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">127&#x02005;mg/dL (7.0&#x02005;mmol/L)</td><td rowspan="1" colspan="1">108&#x02005;mg/dL (6 mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">123&#x02005;mg/dL (6.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1">99&#x02005;mg/dL (5.5&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">104&#x02005;mg/dL (5.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1">97&#x02005;mg/dL (5.4&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">105&#x02005;mg/dL (5.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1">89&#x02005;mg/dL (4.9&#x02005;mmol/L)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">95&#x02005;mg/dL (5.3&#x02005;mmol/L)</td><td rowspan="1" colspan="1">103&#x02005;mg/dL (5.7&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">87&#x02005;mg/dL (4.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1">68&#x02005;mg/dL (3.7&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">105&#x02005;mg/dL (5.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1">77&#x02005;mg/dL (4.3&#x02005;mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">105&#x02005;mg/dL (5.8&#x02005;mmol/L)</td><td rowspan="1" colspan="1">98&#x02005;mg/dL (5.4 mmol/L)</td></tr><tr><td rowspan="1" colspan="1">Normal range</td><td rowspan="1" colspan="1">70-130&#x02005;mg/dL (3.9-7.2&#x02005;mmol/L)</td><td rowspan="1" colspan="1">&#x0003c; 180&#x02005;mg/dL (&#x0003c; 10&#x02005;mmol/L)</td><td rowspan="1" colspan="1">70-130&#x02005;mg/dL (3.9-7.2&#x02005;mmol/L)</td><td rowspan="1" colspan="1">&#x0003c; 180&#x02005;mg/dL (&#x0003c; 10&#x02005;mmol/L)</td><td rowspan="1" colspan="1">70-130&#x02005;mg/dL (3.9-7.2&#x02005;mmol/L)</td><td rowspan="1" colspan="1">&#x0003c; 180&#x02005;mg/dL (&#x0003c; 10&#x02005;mmol/L)</td></tr></tbody></table></table-wrap></sec><sec id="luaf109-s4"><title>Treatment</title><p>Because of suboptimal glycemic control and the absence of hypoglycemic events, insulin glargine U 300 was increased to 16&#x02005;IU and metformin was increased to 1000&#x02005;mg twice daily. Lipid-lowering therapy was also prescribed for elevated low-density lipoprotein (LDL) cholesterol levels.</p><p>At the 6-month follow-up visit, the patient's HbA1c and fasting glucose levels improved (<xref rid="luaf109-T1" ref-type="table">Table 1</xref>). However, the patient declined the use of continuous glucose monitoring (CGM), opting instead for self-reported blood glucose monitoring (SBGM).</p><p>Despite the previous improvement in glycemic control, laboratory results at the 9-month follow-up visit (<xref rid="luaf109-T1" ref-type="table">Table 1</xref>) showed an increase in HbA1c. This was in contrast to the low fasting glucose and trend toward lower glucose levels observed in the SBGM (<xref rid="luaf109-T2" ref-type="table">Table 2</xref>). A capillary blood glucose test 3&#x02005;hours after a meal was 107&#x02005;mg/dL (5.9&#x02005;mmol/L)(normal range: 70-130&#x02005;mg/dL; 3.8-7.2&#x02005;mmol/L), highlighting discrepancies with HbA1c. In addition, there was low pancreatic enzyme activity (lipase and amylase) but normal liver function and no evidence of anemia or blood cell changes (<xref rid="luaf109-T1" ref-type="table">Table 1</xref>). The patient agreed to start using CGM and, given the elevated LDL cholesterol levels, was instructed to improve adherence to prescribed lipid-lowering therapy. An esophagogastroduodenoscopy revealed a small swelling with central umbilication in the lower wall of the gastric antrum, suggesting an aberrant pancreas (<xref rid="luaf109-F1" ref-type="fig">Fig. 1</xref>).</p><fig position="float" id="luaf109-F1" fig-type="figure"><label>Figure 1.</label><caption><p>Esophagogastroduodenoscopy revealing minute swelling with central umbilication located in the gastric antrum, as for aberrant pancreas.</p></caption><graphic xlink:href="luaf109f1" position="float"/></fig></sec><sec id="luaf109-s5"><title>Outcome and Follow-up</title><p>After 3 weeks, analysis of the CGM data showed positive glycemic control with 80% time in range, 20% time above range, 0% time below range, and 6.8% of estimated HbA1c. The coefficient of variation was 32%. Because of occasional postprandial spikes, therapy was intensified by adding rapid-acting insulin (5&#x02005;IU before breakfast, 4&#x02005;IU before lunch, and 4&#x02005;IU before dinner), and the patient was instructed on how to adjust the insulin dose as needed. LDL cholesterol levels improved.</p><p>After an additional 3 weeks, CGM data confirmed that good glycemic control was maintained (<xref rid="luaf109-F2" ref-type="fig">Fig. 2</xref>), achieving a good glycemic and lipid control at 12 months (<xref rid="luaf109-T1" ref-type="table">Table 1</xref>).</p><fig position="float" id="luaf109-F2" fig-type="figure"><label>Figure 2.</label><caption><p>Patient's CGM change before and after treatment.</p></caption><graphic xlink:href="luaf109f2" position="float"/></fig></sec><sec sec-type="discussion" id="luaf109-s6"><title>Discussion</title><p>This case report emphasizes the importance of suspecting T3cDM in patients with a history of HCP or CP [<xref rid="luaf109-B16" ref-type="bibr">16</xref>], especially those with <italic toggle="yes">PRSS1</italic> gene pathogenic variant, which typically result in the <italic toggle="yes">PRSS1</italic> histopathologic imaging triad: pancreatic atrophy, calcification, and ductal dilatation [<xref rid="luaf109-B17" ref-type="bibr">17</xref>], as seen in the patient. Research shows that approximately 80% of individuals with <italic toggle="yes">PRSS1</italic> pathogenic variant have diffuse pancreatic atrophy and 60% have ductal dilatation (6-22&#x02005;mm). In addition, replacement of pancreatic tissue by adipose tissue has been observed, leading to lipomatous atrophy [<xref rid="luaf109-B5" ref-type="bibr">5</xref>], which increases the risk of pancreatic cancer [<xref rid="luaf109-B18" ref-type="bibr">18</xref>]. This highlights the need for regular cancer screening during follow-up [<xref rid="luaf109-B3" ref-type="bibr">3</xref>].</p><p>T3cDM, often called &#x0201c;brittle diabetes,&#x0201d; is characterized by fluctuating blood glucose levels because of both insulin resistance and insulin deficiency [<xref rid="luaf109-B2" ref-type="bibr">2</xref>, <xref rid="luaf109-B9" ref-type="bibr">9</xref>, <xref rid="luaf109-B15" ref-type="bibr">15</xref>]. Currently, there are no standardized treatment guidelines for T3cDM; this can lead to undertreatment or unsafe management [<xref rid="luaf109-B19" ref-type="bibr">19</xref>]. Expert consensus [<xref rid="luaf109-B20" ref-type="bibr">20</xref>] recommends tight glycemic control (HbA1c &#x0003c; 7%) to prevent complications [<xref rid="luaf109-B1" ref-type="bibr">1</xref>].</p><p>First-line treatment includes metformin and insulin [<xref rid="luaf109-B14" ref-type="bibr">14</xref>], especially in cases with HCP [<xref rid="luaf109-B9" ref-type="bibr">9</xref>], tailored to the patient's clinical presentation [<xref rid="luaf109-B14" ref-type="bibr">14</xref>]. Metformin is effective for mild hyperglycemia (HbA1c &#x0003c; 8%) and insulin resistance [<xref rid="luaf109-B21" ref-type="bibr">21</xref>], and may protect against pancreatic cancer [<xref rid="luaf109-B14" ref-type="bibr">14</xref>], a common complication in these patients. However, gastrointestinal side effects can be a limitation [<xref rid="luaf109-B21" ref-type="bibr">21</xref>]. Many patients often require intensified therapy [<xref rid="luaf109-B11" ref-type="bibr">11</xref>, <xref rid="luaf109-B19" ref-type="bibr">19</xref>, <xref rid="luaf109-B21" ref-type="bibr">21</xref>], including early insulin initiation [<xref rid="luaf109-B22" ref-type="bibr">22</xref>], recommended by consensus guidelines for the treatment of insulin deficiency in diabetes secondary to CP [<xref rid="luaf109-B20" ref-type="bibr">20</xref>]. Insulin should be started gradually to avoid hypoglycemia, but higher doses may be needed if insulin resistance is suspected [<xref rid="luaf109-B22" ref-type="bibr">22</xref>]. Experts recommend continuing metformin and other oral agents to reduce insulin doses [<xref rid="luaf109-B10" ref-type="bibr">10</xref>, <xref rid="luaf109-B19" ref-type="bibr">19</xref>], while close monitoring is essential [<xref rid="luaf109-B11" ref-type="bibr">11</xref>].</p><p>The role of other antidiabetic agents remains uncertain [<xref rid="luaf109-B14" ref-type="bibr">14</xref>, <xref rid="luaf109-B19" ref-type="bibr">19</xref>]. Thiazolidinediones carry risks such as bone fractures and fluid retention, whereas sulfonylureas increase the risk of severe hypoglycemia. Incretin-based therapies (glucagon-like peptide-1 receptor agonists and oral dipeptidyl peptidase-4 inhibitors) are avoided because of concerns about pancreatitis. Sodium-glucose cotransporter-2 inhibitors are not recommended for T3cDM until their safety is confirmed with regard to the risk of euglycemic diabetic ketoacidosis in insulin-deficient states [<xref rid="luaf109-B14" ref-type="bibr">14</xref>, <xref rid="luaf109-B21" ref-type="bibr">21</xref>].</p><p>The increased fragility of T3cDM is often associated with a high risk of hypoglycemia. However, in clinical practice, inadequate pancreatic &#x003b2;-cell function and insulin resistance also contribute to higher insulin requirements and poorer glycemic control, particularly in terms of hyperglycemic events [<xref rid="luaf109-B14" ref-type="bibr">14</xref>]. This may explain the higher HbA1c levels in patients with T3cDM compared to those with T2DM [<xref rid="luaf109-B23" ref-type="bibr">23</xref>], as in this patient. Additionally, HbA1c does not accurately reflect daily glucose fluctuations [<xref rid="luaf109-B24" ref-type="bibr">24</xref>], which may not correlate with estimated HbA1c from CGM [<xref rid="luaf109-B25" ref-type="bibr">25</xref>] or SBGM, as shown in this case report.</p><p>Studies using CGM suggest that patients with T3cDM are likely to experience more hyperglycemic episodes. Higher glucose variability (GV) was found in patients with fibrocalcific pancreatic diabetes compared to those with T2DM, mainly attributed to postprandial glucose spikes [<xref rid="luaf109-B26" ref-type="bibr">26</xref>]. Similarly, time above range was found to be higher in totally pancreatectomized patients than in patients with T1DM, despite similar GV [<xref rid="luaf109-B27" ref-type="bibr">27</xref>]. Recent research has shown that patients with T3cDM have higher estimated HbA1c and blood glucose levels, but do not have higher GV compared to those with T1DM and T2DM. In addition, patients with T3cDM had lower C-peptide levels than patients with T2DM, but higher than those with T1DM [<xref rid="luaf109-B28" ref-type="bibr">28</xref>]. These studies did not observe an increased risk of hypoglycemia in T3cDM.</p><p>These findings suggest that although HbA1c levels may not accurately reflect glycemic fluctuations, CGM may provide more accurate management [<xref rid="luaf109-B26" ref-type="bibr">26</xref>, <xref rid="luaf109-B28" ref-type="bibr">28</xref>] and optimize glycemic control in these patients. As demonstrated in this case, despite a stepwise intensification of insulin therapy, the introduction of prandial insulin guided by CGM improved glycemia due to the patient's minimal residual &#x003b2;-cell function and likely contributed to the improvement in the trend toward lower glycemia observed in the SBGM. This underscores the importance of CGM in improving glycemic control and reducing GV, as evidenced by coefficient of variation &#x0003c;36%, which identifies stable vs unstable glycemia [<xref rid="luaf109-B24" ref-type="bibr">24</xref>]. In addition, close patient monitoring allows for a more personalized approach to treatment, with strategies tailored to the specific needs of patients with T3cDM. Although insulin is the most commonly recommended therapy for T3cDM [<xref rid="luaf109-B11" ref-type="bibr">11</xref>], further research using continuous monitoring may explore a broader range of hypoglycemic treatment options once better glycemic control is achieved.</p></sec><sec id="luaf109-s7"><title>Learning Points</title><list list-type="bullet"><list-item><p>T3cDM has unique features that make its diagnosis and management complex and require careful attention from health care providers.</p></list-item><list-item><p>HCP, often associated with the <italic toggle="yes">PRSS1</italic> pathogenic variant, is a primary cause of CP, which can lead to the development of T3cDM.</p></list-item><list-item><p>Given the atypical presentation of T3cDM, it is important to increase awareness and screen for diabetes in patients with CP or HCP, even in the absence of severe exocrine insufficiency symptoms.</p></list-item><list-item><p>Accurate diagnosis of T3cDM requires specific criteria to distinguish it from other forms of diabetes.</p></list-item><list-item><p>Early detection of T3cDM is critical for timely treatment, with close monitoring and the use of technology potentially improving patient outcomes and enabling the exploration of new treatment strategies.</p></list-item></list></sec><sec id="luaf109-s8"><title>Contributors</title><p>All authors made individual contributions to authorship. D.C. and M.C. were involved in the diagnosis and management of the patient and in the manuscript design, G.G. and C.G. collected the data, and I.M. contributed to the original draft writing and prepared the tables and figures. F.L. revised the manuscript and D.C. supervised the manuscript submission. All authors reviewed and approved the final draft.</p></sec></body><back><sec id="luaf109-s9"><title>Funding</title><p>No public or commercial funding.</p></sec><sec id="luaf109-s11"><title>Disclosures</title><p>The authors have nothing to disclose.</p></sec><sec id="luaf109-s12"><title>Informed Patient Consent for Publication</title><p>Signed informed consent was obtained directly from the patient.</p></sec><sec sec-type="data-availability" id="luaf109-s13"><title>Data Availability Statement</title><p>Data sharing is not applicable to this article as no data sets were generated or analyzed during the present study.</p></sec><ref-list id="ref1"><title>References</title><ref id="luaf109-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gudipaty</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Rickels</surname> &#x000a0;<given-names>MR</given-names></string-name></person-group>. <article-title>Pancreatogenic (Type 3c) diabetes</article-title>. <source>Pancreapedia: The Exocrine Pancreas Knowledge Base</source>. <year>2015</year>. Doi: <pub-id pub-id-type="doi">10.3998/panc.2015.35</pub-id></mixed-citation></ref><ref id="luaf109-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wayne</surname> &#x000a0;<given-names>CD</given-names></string-name>, <string-name><surname>Benbetka</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Besner</surname> &#x000a0;<given-names>GE</given-names></string-name>, <string-name><surname>Narayanan</surname> &#x000a0;<given-names>S</given-names></string-name></person-group>. <article-title>Challenges of managing type 3c diabetes in the context of pancreatic resection, cancer and trauma</article-title>. <source>J Clin Med</source>. <year>2024</year>;<volume>13</volume>(<issue>10</issue>):<fpage>2993</fpage>.<pub-id pub-id-type="pmid">38792534</pub-id>
</mixed-citation></ref><ref id="luaf109-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Valente</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Waldthaler</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Scandavini</surname> &#x000a0;<given-names>CM</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>conservative treatment of chronic pancreatitis: a practical approach</article-title>. <source>Scand J Surg</source>. <year>2020</year>;<volume>109</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02010;<lpage>68</lpage>.<pub-id pub-id-type="pmid">32192418</pub-id>
</mixed-citation></ref><ref id="luaf109-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shelton</surname> &#x000a0;<given-names>CA</given-names></string-name>, <string-name><surname>Whitcomb</surname> &#x000a0;<given-names>DC</given-names></string-name></person-group>. <article-title>Genetics and treatments options for recurrent acute and chronic pancreatitis</article-title>. <source>Curr Treat Options Gastroenterol</source>. <year>2014</year>;<volume>12</volume>(<issue>3</issue>):<fpage>359</fpage>&#x02010;<lpage>371</lpage>.<pub-id pub-id-type="pmid">24954874</pub-id>
</mixed-citation></ref><ref id="luaf109-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Singhi</surname> &#x000a0;<given-names>AD</given-names></string-name>, <string-name><surname>Pai</surname> &#x000a0;<given-names>RK</given-names></string-name>, <string-name><surname>Kant</surname> &#x000a0;<given-names>JA</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>The histopathology of PRSS1 hereditary pancreatitis</article-title>. <source>Am J Surg Pathol</source>. <year>2014</year>;<volume>38</volume>(<issue>3</issue>):<fpage>346</fpage>&#x02010;<lpage>353</lpage>.<pub-id pub-id-type="pmid">24525505</pub-id>
</mixed-citation></ref><ref id="luaf109-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>N&#x000e9;meth</surname> &#x000a0;<given-names>BC</given-names></string-name>, <string-name><surname>Patai</surname> &#x000a0;<given-names>&#x000c1;V</given-names></string-name>, <string-name><surname>Sahin-T&#x000f3;th</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Hegyi</surname> &#x000a0;<given-names>P</given-names></string-name></person-group>. <article-title>Misfolding cationic trypsinogen variant p.L104P causes hereditary pancreatitis</article-title>. <source>Gut</source>. <year>2017</year>;<volume>66</volume>(<issue>9</issue>):<fpage>1727</fpage>&#x02010;<lpage>1728</lpage>.<pub-id pub-id-type="pmid">28011893</pub-id>
</mixed-citation></ref><ref id="luaf109-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bal&#x000e1;zs</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Hegyi</surname> &#x000a0;<given-names>P</given-names></string-name>, <string-name><surname>Sahin-T&#x000f3;th</surname> &#x000a0;<given-names>M</given-names></string-name></person-group>. <article-title>Pathogenic cellular role of the p.L104P human cationic trypsinogen variant in chronic pancreatitis</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2016</year>;<volume>310</volume>(<issue>7</issue>):<fpage>G477</fpage>&#x02010;<lpage>G486</lpage>.<pub-id pub-id-type="pmid">26822915</pub-id>
</mixed-citation></ref><ref id="luaf109-B8"><label>8</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<string-name>
<surname>Shelton</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Solomon</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>LaRusch</surname>, <given-names>J.</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>PRSS1-Related Hereditary pancreatitis. 2012 Mar 1 [Updated 2019 Apr 25]</article-title>. <person-group person-group-type="editor"><string-name><surname>Adam</surname> &#x000a0;<given-names>MP</given-names></string-name>, <string-name><surname>Feldman</surname> &#x000a0;<given-names>J</given-names></string-name>, <string-name><surname>Mirzaa</surname> &#x000a0;<given-names>GM</given-names></string-name>, <etal>et al</etal></person-group>, editors (<publisher-loc>WA</publisher-loc>): <publisher-name>University of Washington, Seattle</publisher-name>; <fpage>1993</fpage>&#x02010;<lpage>2025</lpage>. (<year>2019</year>)</mixed-citation></ref><ref id="luaf109-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Richardson</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Park</surname> &#x000a0;<given-names>WG</given-names></string-name></person-group>. <article-title>Acute pancreatitis and diabetes mellitus: a review</article-title>. <source>Korean J Intern Med</source>. <year>2021</year>;<volume>36</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02010;<lpage>24</lpage>.<pub-id pub-id-type="pmid">33147904</pub-id>
</mixed-citation></ref><ref id="luaf109-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Duggan</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Conlon</surname> &#x000a0;<given-names>K</given-names></string-name></person-group>. <article-title>Pancreatogenic type 3c diabetes: underestimated, underappreciated, and poorly managed</article-title>. <source>Pract Gastroenterol</source>. <year>2017</year>;<volume>163</volume>:<fpage>14</fpage>&#x02010;<lpage>23</lpage>.</mixed-citation></ref><ref id="luaf109-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Vonderau</surname> &#x000a0;<given-names>JS</given-names></string-name>, <string-name><surname>Desai</surname> &#x000a0;<given-names>CS</given-names></string-name></person-group>. <article-title>Type 3c: understanding pancreatogenic diabetes</article-title>. <source>JAAPA</source>. <year>2022</year>;<volume>35</volume>(<issue>11</issue>):<fpage>20</fpage>.</mixed-citation></ref><ref id="luaf109-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>American Diabetes Association Professional Practice Committee</collab>
</person-group>. <article-title>2. diagnosis and classification of diabetes: standards of care in diabetes&#x02014;2024</article-title>. <source>Diabetes Care</source>. <year>2024</year>;<volume>47</volume>(<issue>Suppl_1</issue>):<fpage>S20</fpage>&#x02010;<lpage>S42</lpage>.<pub-id pub-id-type="pmid">38078589</pub-id>
</mixed-citation></ref><ref id="luaf109-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Makuc</surname> &#x000a0;<given-names>J</given-names></string-name>
</person-group>. <article-title>Management of pancreatogenic diabetes: challenges and solutions</article-title>. <source>DMSO</source>. <year>2016</year>;<volume>9</volume>:<fpage>311</fpage>&#x02010;<lpage>315</lpage>.</mixed-citation></ref><ref id="luaf109-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hart</surname> &#x000a0;<given-names>PA</given-names></string-name>, <string-name><surname>Bellin</surname> &#x000a0;<given-names>MD</given-names></string-name>, <string-name><surname>Andersen</surname> &#x000a0;<given-names>DK</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2016</year>;<volume>1</volume>(<issue>3</issue>):<fpage>226</fpage>&#x02010;<lpage>237</lpage>.<pub-id pub-id-type="pmid">28404095</pub-id>
</mixed-citation></ref><ref id="luaf109-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dytz</surname> &#x000a0;<given-names>MG</given-names></string-name>, <string-name><surname>Marcelino</surname> &#x000a0;<given-names>PAH</given-names></string-name>, <string-name><surname>de Castro Santos</surname> &#x000a0;<given-names>O</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Clinical aspects of pancreatogenic diabetes secondary to hereditary pancreatitis</article-title>. <source>Diabetol Metab Syndr</source>. <year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>4</fpage>.<pub-id pub-id-type="pmid">28101143</pub-id>
</mixed-citation></ref><ref id="luaf109-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>&#x0015a;liwi&#x00144;ska-Mosso&#x00144;</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Milnerowicz</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Milnerowicz</surname> &#x000a0;<given-names>H</given-names></string-name></person-group>. <article-title>Diabetes mellitus secondary to pancreatic diseases (type 3c): the effect of smoking on the exocrine&#x02013;endocrine interactions of the pancreas</article-title>. <source>Diab Vasc Dis Res</source>. <year>2018</year>;<volume>15</volume>(<issue>3</issue>):<fpage>243</fpage>&#x02010;<lpage>259</lpage>.<pub-id pub-id-type="pmid">29558826</pub-id>
</mixed-citation></ref><ref id="luaf109-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ge</surname> &#x000a0;<given-names>Q-C</given-names></string-name>, <string-name><surname>Dietrich</surname> &#x000a0;<given-names>CF</given-names></string-name>, <string-name><surname>Bhutani</surname> &#x000a0;<given-names>MS</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Comprehensive review of diagnostic modalities for early chronic pancreatitis</article-title>. <source>World J Gastroenterol</source>. <year>2021</year>;<volume>27</volume>(<issue>27</issue>):<fpage>4342</fpage>&#x02010;<lpage>4357</lpage>.<pub-id pub-id-type="pmid">34366608</pub-id>
</mixed-citation></ref><ref id="luaf109-B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Desai</surname> &#x000a0;<given-names>V</given-names></string-name>, <string-name><surname>Patel</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Sheth</surname> &#x000a0;<given-names>R</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Pancreatic fat infiltration is associated with a higher risk of pancreatic ductal adenocarcinoma</article-title>. <source>Visc Med</source>. <year>2020</year>;<volume>36</volume>(<issue>3</issue>):<fpage>220</fpage>&#x02010;<lpage>226</lpage>.<pub-id pub-id-type="pmid">32775353</pub-id>
</mixed-citation></ref><ref id="luaf109-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Goodarzi</surname> &#x000a0;<given-names>MO</given-names></string-name>, <string-name><surname>Petrov</surname> &#x000a0;<given-names>MS</given-names></string-name></person-group>. <article-title>Diabetes of the exocrine pancreas: implications for pharmacological management</article-title>. <source>Drugs</source>. <year>2023</year>;<volume>83</volume>(<issue>12</issue>):<fpage>1077</fpage>&#x02010;<lpage>1090</lpage>.<pub-id pub-id-type="pmid">37410209</pub-id>
</mixed-citation></ref><ref id="luaf109-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Rickels</surname> &#x000a0;<given-names>MR</given-names></string-name>, <string-name><surname>Bellin</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Toledo</surname> &#x000a0;<given-names>FGS</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from <italic toggle="yes">PancreasFest</italic> 2012</article-title>. <source>Pancreatology</source>. <year>2013</year>;<volume>13</volume>(<issue>4</issue>):<fpage>336</fpage>&#x02010;<lpage>342</lpage>.<pub-id pub-id-type="pmid">23890130</pub-id>
</mixed-citation></ref><ref id="luaf109-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>L&#x000f6;hr</surname> &#x000a0;<given-names>JM</given-names></string-name>, <string-name><surname>Dominguez-Munoz</surname> &#x000a0;<given-names>E</given-names></string-name>, <string-name><surname>Rosendahl</surname> &#x000a0;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)</article-title>. <source>United European Gastroenterol J</source>. <year>2017</year>;<volume>5</volume>(<issue>2</issue>):<fpage>153</fpage>&#x02010;<lpage>199</lpage>.</mixed-citation></ref><ref id="luaf109-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wynne</surname> &#x000a0;<given-names>K</given-names></string-name>, <string-name><surname>Devereaux</surname> &#x000a0;<given-names>B</given-names></string-name>, <string-name><surname>Dornhorst</surname> &#x000a0;<given-names>A</given-names></string-name></person-group>. <article-title>Diabetes of the exocrine pancreas</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2019</year>;<volume>34</volume>(<issue>2</issue>):<fpage>346</fpage>&#x02010;<lpage>354</lpage>.<pub-id pub-id-type="pmid">30151918</pub-id>
</mixed-citation></ref><ref id="luaf109-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>&#x0015a;liwi&#x00144;ska-Mosso&#x00144;</surname> &#x000a0;<given-names>M</given-names></string-name>, <string-name><surname>Bil-Lula</surname> &#x000a0;<given-names>I</given-names></string-name>, <string-name><surname>Marek</surname> &#x000a0;<given-names>G</given-names></string-name></person-group>. <article-title>The cause and effect relationship of diabetes after acute pancreatitis</article-title>. <source>Biomedicines</source>. <year>2023</year>;<volume>11</volume>(<issue>3</issue>):<fpage>667</fpage>.<pub-id pub-id-type="pmid">36979645</pub-id>
</mixed-citation></ref><ref id="luaf109-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Danne</surname> &#x000a0;<given-names>T</given-names></string-name>, <string-name><surname>Nimri</surname> &#x000a0;<given-names>R</given-names></string-name>, <string-name><surname>Battelino</surname> &#x000a0;<given-names>T</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>International consensus on use of continuous glucose monitoring</article-title>. <source>Diabetes Care</source>. <year>2017</year>;<volume>40</volume>(<issue>12</issue>):<fpage>1631</fpage>&#x02010;<lpage>1640</lpage>.<pub-id pub-id-type="pmid">29162583</pub-id>
</mixed-citation></ref><ref id="luaf109-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Beck</surname> &#x000a0;<given-names>RW</given-names></string-name>, <string-name><surname>Connor</surname> &#x000a0;<given-names>CG</given-names></string-name>, <string-name><surname>Mullen</surname> &#x000a0;<given-names>DM</given-names></string-name>, <string-name><surname>Wesley</surname> &#x000a0;<given-names>DM</given-names></string-name>, <string-name><surname>Bergenstal</surname> &#x000a0;<given-names>RM</given-names></string-name></person-group>. <article-title>The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading</article-title>. <source>Diabetes Care</source>. <year>2017</year>;<volume>40</volume>(<issue>8</issue>):<fpage>994</fpage>&#x02010;<lpage>999</lpage>.<pub-id pub-id-type="pmid">28733374</pub-id>
</mixed-citation></ref><ref id="luaf109-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shivaprasad</surname> &#x000a0;<given-names>C</given-names></string-name>, <string-name><surname>Aiswarya</surname> &#x000a0;<given-names>Y</given-names></string-name>, <string-name><surname>Kejal</surname> &#x000a0;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Comparison of CGM-derived measures of glycemic variability between pancreatogenic diabetes and Type 2 diabetes Mellitus</article-title>. <source>J Diabetes Sci Technol</source>. <year>2021</year>;<volume>15</volume>(<issue>1</issue>):<fpage>134</fpage>&#x02010;<lpage>140</lpage>.<pub-id pub-id-type="pmid">31282179</pub-id>
</mixed-citation></ref><ref id="luaf109-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Juel</surname> &#x000a0;<given-names>CTB</given-names></string-name>, <string-name><surname>Dejgaard</surname> &#x000a0;<given-names>TF</given-names></string-name>, <string-name><surname>Hansen</surname> &#x000a0;<given-names>CP</given-names></string-name>, <etal>et al</etal></person-group> &#x000a0;<article-title>Glycemic control and variability of diabetes secondary to total pancreatectomy assessed by continuous glucose monitoring</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2021</year>;<volume>106</volume>(<issue>1</issue>):<fpage>168</fpage>&#x02010;<lpage>173</lpage>.<pub-id pub-id-type="pmid">33053154</pub-id>
</mixed-citation></ref><ref id="luaf109-B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname> &#x000a0;<given-names>VTY</given-names></string-name>, <string-name><surname>Poynten</surname> &#x000a0;<given-names>A</given-names></string-name>, <string-name><surname>Depczynski</surname> &#x000a0;<given-names>B</given-names></string-name></person-group>. <article-title>Continuous glucose monitoring to assess glucose variability in type 3c diabetes</article-title>. <source>Diabet Med</source>. <year>2022</year>;<volume>39</volume>(<issue>8</issue>):<fpage>e14882</fpage>.<pub-id pub-id-type="pmid">35569007</pub-id>
</mixed-citation></ref></ref-list></back></article>